26. HTLV-1-associated myelopathy Clinical trials / Disease details

Clinical trials : 28 / Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00324	29/06/2017	23/01/2018	A Phase 3 Study of KW-0761 (Mogamulizumab) in Subjects with HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM)	HTLV-1 associated Myelopathy (HAM)	Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP.	Kyowa Kirin Co., Ltd	NULL	Completed	>=20 YEARS	No Limit	BOTH	52	Phase 3	Japan
2	JPRN-JapicCTI-173608	01/6/2017	06/06/2017	A Phase 3 Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM)	HTLV-1 associated Myelopathy (HAM)	Intervention name : KW-0761 INN of the intervention : Mogamulizumab Dosage And administration of the intervention : 0.3 mg/kg, IV	Kyowa Hakko Kirin Co., Ltd.	NULL	complete	20		BOTH	52	Phase 3	NULL
3	NCT03191526 (ClinicalTrials.gov)	May 22, 2017	13/6/2017	A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)	A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)	HTLV-1 Associated Myelopathy	Drug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline)	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	N/A	All	66	Phase 3	Japan